GEXVal Receives EMA’s CHMP Scientific Advice for Lead Pipeline GXV-001
2026/5/21
GEXVal Inc.May 21, 2026 GEXVal Receives Scientific Advice from EMA’s CHMP for Lead Pipeline GXV-001 in Fragile […]
GEXVal Selected as Presenting Company at BioEquity Europe 2026
2026/5/7
GEXVal Inc.May 7, 2026 GEXVal CEO Selected to Present at BioEquity Europe 2026 GEXVal Inc. (President & […]
GEXVal CEO Selected as Invited Speaker at CPHI Japan 2026
2026/4/15
GEXVal Inc.April 15, 2026 GEXVal CEO Selected as Invited Speaker at Drug Discovery Symposium of CPHI Japan 202 […]
Announcement of Appointment of External Director
2026/3/25
GEXVal Inc.March 25, 2026 Unlocking the Value of Drug Discovery Through IP Strategy — Appointment of of Dr. Ka […]
GEXVal CTO to Present at the Annual Meeting of the PSJ
2026/3/25
GEXVal Inc.March 25, 2026 GEXVal CTO to Present at the 146th Annual Meeting of the Pharmaceutical Society of J […]